title: Impact of types of lymphocyte chromosomal aberrations on human cancer risk: results from Nordic and Italian cohorts.
abstract: The frequency of cells with structural chromosomal aberrations (CAs) in peripheral blood lymphocytes is the first genotoxicity biomarker that has shown an association with cancer risk. CAs are usually divided into chromosome-type (CSAs) and chromatid-type aberrations (CTAs), with different mechanisms of formation. From a mechanistic point of view, it is of interest to clarify whether the cancer predictivity of CAs is different with respect to CSAs and CTAs. We report here cancer risk for cytogenetically tested, healthy subjects with respect to frequency of CAs, CSAs, and CTAs in peripheral blood lymphocytes, using Nordic (1981 subjects with CA data, 1871 subjects with CSA/CTA data) and Italian (1573 subjects with CA data, 877 subjects with CTA/CSA data) cohorts, with a median follow-up of 17 years. High levels of CAs at test were clearly associated with increased total cancer incidence in the Nordic cohorts and increased total cancer mortality in the Italian cohort. In the Nordic cohorts, significantly elevated cancer risks were observed for subjects with both high CSAs and high CTAs at test, and these variables showed equally strong cancer predictivity. The results of the Italian cohort did not indicate any clear-cut difference in cancer predictivity between the CSA and CTA biomarkers. There was no significant effect modification by age at test, gender, country, or time since test. The results suggest that both DNA double-strand breaks and other initial DNA lesions responsible for CSAs and CTAs are associated with cancer risk.
authors.affiliation: Department of Occupational and Environmental Medicine, Lund University Hospital, SE-221 85 Lund, Sweden. lars.hagmar@ymed.lu.se
authors.forename: Lars
authors.initials: L
authors.lastname: Hagmar
authors.forename: Ulf
authors.initials: U
authors.lastname: Strömberg
authors.forename: Stefano
authors.initials: S
authors.lastname: Bonassi
authors.forename: Inger-Lise
authors.initials: IL
authors.lastname: Hansteen
authors.forename: Lisbeth Ehlert
authors.initials: LE
authors.lastname: Knudsen
authors.forename: Carita
authors.initials: C
authors.lastname: Lindholm
authors.forename: Hannu
authors.initials: H
authors.lastname: Norppa
mesh_terms: D002842:Chromatids; D002869:Chromosome Aberrations; D002877:Chromosomes, Human / Q000235:genetics*; D015331:Cohort Studies; D005387:Finland / Q000453:epidemiology; D005500:Follow-Up Studies; D005819:Genetic Markers; D006801:Humans; D007558:Italy / Q000453:epidemiology; D008214:Lymphocytes; D009369:Neoplasms / Q000175:diagnosis / Q000235:genetics* / Q000401:mortality; D009664:Norway / Q000453:epidemiology; D012307:Risk Factors; D012537:Scandinavian and Nordic Countries / Q000453:epidemiology; D012854:Sister Chromatid Exchange; D015996:Survival Rate; D013548:Sweden / Q000453:epidemiology
chemical_list: D005819:Genetic Markers